Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores

References

• Watson, DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2(COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160, 2998–3003 (2000).
   PubMed Web of Science ®Google Scholar
• Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J. Rheumatol. 26(Suppl. 26), 18–24 (1999).
   Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faigh G, Goldstein JL et al. Gastrointestinal toxicity celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. JAMA 284, 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Weis MR, Sperling RS, Reicin A, Gertz BJ. Selective COX- 2 inhibition and cardiovascular effects: a review of rofecoxib development program. Am. Heart J. 146, 591–604 (2003).
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature New Biol. 231, 235–239 (1971).
   PubMedGoogle Scholar
• Henry D, Lim LLY, Rodriguez LAG et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. 312, 1563–1566 (1996).
   PubMed Web of Science ®Google Scholar
• Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression:a new model applied to chronic NSAID use. Pain 85, 169–182 (2000).
   PubMed Web of Science ®Google Scholar
• Memorandum from David J Graham, associate director for Science, office of Drug Safety to Paul Seligman, acting Director, Office of Drug Safety entitled, ‘Risk of Acute Myocardial Infarction and Sudden Cardiac Death in Patients Treated with COX-2 Selective and Non-Selective NSAIDs,’ September 30 ( 2004).
   Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 364, 665–674 (2004).
   PubMed Web of Science ®Google Scholar
• Norgard B, Pedersen L, Johnsen SP et al. ‘COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment. Pharmacol. Ther. 19(7), 817–825 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Zhao SZ, Burke TA, Palmer R, von Allmen H, Henderson SC. Incidence of out-patient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States. Am. J. Gastroenterol. 98(12), 2627–2634 (2003).
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment. Pharmacol. Ther. 19(11), 1189–1198 (2004).
   PubMed Web of Science ®Google Scholar
• Lisse JR, Perlman M, Johansson G et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial [see comment]. Ann. Intern. Med. 139(7), 539–546 (2003)
   PubMed Web of Science ®Google Scholar
• Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective –1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol. 51(Suppl.), 8–16 (1998).
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 340, 1888–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am. J. Gastroenterol. 87, 1398–1402 (1992).
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann. Intern. Med. 115, 787–796 (1991).
   PubMed Web of Science ®Google Scholar
• Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology 120, 594–606 (2001).
   PubMed Web of Science ®Google Scholar
• Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am. J. Med. 91, 213–222 (1991).
   PubMed Web of Science ®Google Scholar
• Lanes SF, Lanza LL, Radensky PW et al. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum. 40, 1475–1481 (1997).
   PubMed Web of Science ®Google Scholar
• Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. 312(7046), 1563–1566 (1997).
   Google Scholar
• Wolfe F, Kong SX, Watson DJ, Gastrointestinal symptoms and health related quality of life in patients with arthritis, J. Rheumatol. 27(6), 1373–1378 (2000).
   PubMed Web of Science ®Google Scholar
• Watson, DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2(COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160, 2998–3003 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41–55 (1983).
   Web of Science ®Google Scholar
• Sweet BV, Townsend KA, Tsai CY. Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. Am. J. Health Syst. Pharm. 61, 1917–1921 (2004).
   PubMed Web of Science ®Google Scholar
• Shaya FT, Samant N, Kim J. Nonselective cyclooxygenase inhibition and gastrointestinal effects: a review of recent clinical observations. Med. Hypotheses 2(2), 401–411 (2005).
   Google Scholar
• Shaya FT, Blume SW, Blanchette CM et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population, Arch. Intern. Med. 165(2), 181–186 (2005).
   PubMedGoogle Scholar
• Shaya FT, Gu S. Assessing potential risks and evaluating expected benefits. Manage. Care Interface 18(5), 27–30 (2004).
   Google Scholar